Please enable JavaScript to continue using this application.

Compare $ERAS vs $IMVT | Chartloom

Compare

$ERAS vs $IMVT

Erasca Inc · Immunovant Inc

ERAS

Erasca Inc

IMVT

Immunovant Inc

Compare $ERAS vs $IMVT

Comparing Erasca Inc and Immunovant Inc

ERASErasca Inc

IMVTImmunovant Inc

ERASErasca Inc

Market cap

$5.49B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

346.5%

52W performance

559.7%

FCF yield

-1.8%

IMVTImmunovant Inc

Market cap

$6.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

17.6%

52W performance

89.5%

FCF yield

-6.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ERAS

IMVT

Detailed metrics comparison

ERAS

Erasca Inc

IMVT

Immunovant Inc

Market Cap

ERAS$5.49B

IMVT$6.29B

Enterprise Value

ERAS$5.44B

IMVT$5.49B

Price

ERAS$16.03

IMVT$30.47

P/E Ratio

ERASN/A

IMVTN/A

P/S Ratio

ERAS0.00x

IMVT0.00x

EV/Sales

ERAS0.00x

IMVT0.00x

EV/EBITDA

ERAS0.00x

IMVT0.00x

P/B Ratio

ERAS14.25x

IMVT9.44x

P/FCF Ratio

ERASN/A

IMVTN/A

EV/FCF

ERAS-55.50x

IMVT-13.25x

PEG Ratio

ERASN/A

IMVTN/A

Forward P/E (NTM)

ERASN/A

IMVTN/A

Forward P/S (NTM)

ERASN/A

IMVTN/A

Revenue (TTM)

ERAS$0

IMVT$0

Revenue Growth (YoY)

ERASN/A

IMVTN/A

Forward Rev Growth

ERAS959.7%

IMVT546.2%

Gross Margin (TTM)

ERAS0.0%

IMVT0.0%

Operating Margin (TTM)

ERAS0.0%

IMVT0.0%

EBITDA Margin (TTM)

ERAS0.0%

IMVT0.0%

Net Margin (TTM)

ERAS0.0%

IMVT0.0%

FCF Margin (TTM)

ERASN/A

IMVTN/A

Net Income (TTM)

ERAS$-287M

IMVT$-538M

FCF (TTM)

ERAS$-98M

IMVT$-414M

EPS (TTM)

ERAS-$0.92

IMVT-$2.62

ROE (TTM)

ERAS-8043.0%

IMVT-6959.0%

ROA (TTM)

ERAS-6708.0%

IMVT-6250.0%

ROIC (TTM)

ERAS-8043.0%

IMVT-6959.0%

Cash

ERAS$43M

IMVT$798M

Debt

ERAS$0

IMVT$0

Net Cash/Debt

ERAS$43M

IMVT$798M

Current Ratio (TTM)

ERAS8.29x

IMVT7.27x

Quick Ratio (TTM)

ERAS8.08x

IMVT6.82x

Debt/Equity (TTM)

ERAS0.00x

IMVT0.00x

Debt/Assets (TTM)

ERAS0.0%

IMVT0.0%

Interest Coverage (TTM)

ERASN/A

IMVTN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

IMVT0.00x

Beta

ERAS0.67

IMVT0.92

52W Performance

ERAS559.7%

IMVT89.5%

YTD Performance

ERAS346.5%

IMVT17.6%

% from 52W High

ERAS-34.0%

IMVT-32.9%

% from 52W Low

ERAS661.5%

IMVT89.5%

Asset Turnover (TTM)

ERAS0.00x

IMVT0.00x

FCF Yield (TTM)

ERAS-1.8%

IMVT-6.6%

Earnings Yield (TTM)

ERAS-5.2%

IMVT-8.6%

Dividend Yield (TTM)

ERASN/A

IMVTN/A

Rule of 40

ERAS0.0

IMVT0.0

EV/GP/RG

ERASN/A

IMVTN/A

Ticker research

View ERAS research View IMVT research

Metric	ERAS Erasca Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$5.49B	$6.29B
Enterprise Value	$5.44B	$5.49B
Price	$16.03	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	14.25x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	959.7%	546.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-287M	$-538M
FCF (TTM)	$-98M	$-414M
EPS (TTM)	-$0.92	-$2.62
ROE (TTM)	-8043.0%	-6959.0%
ROA (TTM)	-6708.0%	-6250.0%
ROIC (TTM)	-8043.0%	-6959.0%
Financial Health
Cash	$43M	$798M
Debt	$0	$0
Net Cash/Debt	$43M	$798M
Current Ratio (TTM)	8.29x	7.27x
Quick Ratio (TTM)	8.08x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.92
52W Performance	559.7%	89.5%
YTD Performance	346.5%	17.6%
% from 52W High	-34.0%	-32.9%
% from 52W Low	661.5%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-1.8%	-6.6%
Earnings Yield (TTM)	-5.2%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ERAS research	View IMVT research

Valuation

P/S Ratio

ERAS

0.00x

IMVT

0.00x

EV/FCF

ERAS

-55.50x

IMVT

-13.25x

Growth & revenue

Forward Revenue Growth

ERAS

959.7%

IMVT

546.2%

Profitability & performance

Gross Margin

ERAS

0.0%

IMVT

0.0%

ROE

IMVT

-6959.0%

ERAS

-8043.0%

FCF Yield %

ERAS

-1.8%

IMVT

-6.6%

52-Week Performance

ERAS

559.7%

IMVT

89.5%

Detailed metrics comparison

ERAS

Erasca Inc

IMVT

Immunovant Inc

Market Cap

ERAS$5.49B

IMVT$6.29B

Enterprise Value

ERAS$5.44B

IMVT$5.49B

Price

ERAS$16.03

IMVT$30.47

P/E Ratio

ERASN/A

IMVTN/A

P/S Ratio

ERAS0.00x

IMVT0.00x

EV/Sales

ERAS0.00x

IMVT0.00x

EV/EBITDA

ERAS0.00x

IMVT0.00x

P/B Ratio

ERAS14.25x

IMVT9.44x

P/FCF Ratio

ERASN/A

IMVTN/A

EV/FCF

ERAS-55.50x

IMVT-13.25x

PEG Ratio

ERASN/A

IMVTN/A

Forward P/E (NTM)

ERASN/A

IMVTN/A

Forward P/S (NTM)

ERASN/A

IMVTN/A

Revenue (TTM)

ERAS$0

IMVT$0

Revenue Growth (YoY)

ERASN/A

IMVTN/A

Forward Rev Growth

ERAS959.7%

IMVT546.2%

Gross Margin (TTM)

ERAS0.0%

IMVT0.0%

Operating Margin (TTM)

ERAS0.0%

IMVT0.0%

EBITDA Margin (TTM)

ERAS0.0%

IMVT0.0%

Net Margin (TTM)

ERAS0.0%

IMVT0.0%

FCF Margin (TTM)

ERASN/A

IMVTN/A

Net Income (TTM)

ERAS$-287M

IMVT$-538M

FCF (TTM)

ERAS$-98M

IMVT$-414M

EPS (TTM)

ERAS-$0.92

IMVT-$2.62

ROE (TTM)

ERAS-8043.0%

IMVT-6959.0%

ROA (TTM)

ERAS-6708.0%

IMVT-6250.0%

ROIC (TTM)

ERAS-8043.0%

IMVT-6959.0%

Cash

ERAS$43M

IMVT$798M

Debt

ERAS$0

IMVT$0

Net Cash/Debt

ERAS$43M

IMVT$798M

Current Ratio (TTM)

ERAS8.29x

IMVT7.27x

Quick Ratio (TTM)

ERAS8.08x

IMVT6.82x

Debt/Equity (TTM)

ERAS0.00x

IMVT0.00x

Debt/Assets (TTM)

ERAS0.0%

IMVT0.0%

Interest Coverage (TTM)

ERASN/A

IMVTN/A

Net Debt/EBITDA (TTM)

ERAS0.00x

IMVT0.00x

Beta

ERAS0.67

IMVT0.92

52W Performance

ERAS559.7%

IMVT89.5%

YTD Performance

ERAS346.5%

IMVT17.6%

% from 52W High

ERAS-34.0%

IMVT-32.9%

% from 52W Low

ERAS661.5%

IMVT89.5%

Asset Turnover (TTM)

ERAS0.00x

IMVT0.00x

FCF Yield (TTM)

ERAS-1.8%

IMVT-6.6%

Earnings Yield (TTM)

ERAS-5.2%

IMVT-8.6%

Dividend Yield (TTM)

ERASN/A

IMVTN/A

Rule of 40

ERAS0.0

IMVT0.0

EV/GP/RG

ERASN/A

IMVTN/A

Ticker research

View ERAS research View IMVT research

Metric	ERAS Erasca Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$5.49B	$6.29B
Enterprise Value	$5.44B	$5.49B
Price	$16.03	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	14.25x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-55.50x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	959.7%	546.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-287M	$-538M
FCF (TTM)	$-98M	$-414M
EPS (TTM)	-$0.92	-$2.62
ROE (TTM)	-8043.0%	-6959.0%
ROA (TTM)	-6708.0%	-6250.0%
ROIC (TTM)	-8043.0%	-6959.0%
Financial Health
Cash	$43M	$798M
Debt	$0	$0
Net Cash/Debt	$43M	$798M
Current Ratio (TTM)	8.29x	7.27x
Quick Ratio (TTM)	8.08x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.92
52W Performance	559.7%	89.5%
YTD Performance	346.5%	17.6%
% from 52W High	-34.0%	-32.9%
% from 52W Low	661.5%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-1.8%	-6.6%
Earnings Yield (TTM)	-5.2%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View ERAS research	View IMVT research